APM
ALDX icon

Avidity Partners Management’s Aldeyra Therapeutics ALDX Stock Holding History

Avidity Partners Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,450,000
Closed -$16.4M – 106
2021
Q2 		$16.4M Sell
1,450,000
-1,102,000
-43% -$13.3M 0.44% 57
2021
Q1 		$30.3M Buy
2,552,000
+1,117,000
+78% +$12.9M 0.84% 43
2020
Q4 		$9.84M Buy
1,435,000
+5,000
+0.3% +$35.1K 0.32% 67
2020
Q3 		$10.6M Buy
+1,430,000
New +$9.24M 0.49% 46

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Avidity Partners Management's ALDX Position: Q3 2021 in Review

Avidity Partners Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 1,450,000 shares — an estimated $16.4M sold.

Avidity Partners Management first reported a position in ALDX in Q3 2020 and held it in 4 quarters. The position peaked at $30.3M in Q1 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • Avidity Partners Management reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Avidity Partners Management sold 1,450,000 Aldeyra Therapeutics shares in Q3 2021, an estimated $16.4M.
  • Avidity Partners Management first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 4 quarters.
  • Avidity Partners Management's Aldeyra Therapeutics position peaked at $30.3M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.